CTT Pharma Gives Update On U.S. and European Patents

Rhea-AI Summary

CTT Pharmaceutical Holdings (OTC PINK:CTTH) has received notification of an intention to grant from the European Patent Office (EPO) for additional claims to their original European Patent. The company already received an intention to grant for their micelle delivery technology but chose to further define and strengthen their patent specifically for diabetes-related drugs.

With the patent for the diabetes drug Liraglutide having expired, CTT plans to explore opportunities to utilize their micelle technology for this medication. The company believes their technology could provide an enhanced drug delivery system for pharmaceutical companies with current patented diabetes drugs and those in development.

CTT is actively strengthening their patents in both the United States and Europe and intends to file provisional patents in 2025 to further protect their technology. The company has committed to updating shareholders on additional provisional patents once filed and how they will support future development.

Positive

• Received intention to grant from European Patent Office for additional patent claims
• Opportunity to apply micelle technology to off-patent diabetes drug Liraglutide
• Potential to enhance delivery systems for current patented diabetes drugs
• Plans to strengthen patent portfolio in US and Europe with new filings in 2025

Negative

• None.

TAMPA, FL / ACCESS Newswire / February 25, 2025 / CTT Pharmaceutical Holdings, Inc. (OTC PINK:CTTH) has received notification of an intention to grant from the European Patent Office(EPO) for additional claims to our original European Patent. CTT Pharma already received an intention to grant from the EPO for our micelle delivery but opted to further define and strengthen our patent for diabetes related drugs. Since, the patent for the diabetes drug Liraglutide has expired CTT will seek to find opportunities to utilize our micelle technology for Liraglutide. CTT also believes our technology could offer an enhanced drug delivery system for pharmaceutical companies with current diabetes drugs that are patented and for drugs in development. Furthermore, CTT is actively working on strengthening our patents in the United States and Europe and will look to file provisional patents in 2025 to continue to protect and strengthen our technology. CTT will update shareholders on additional provisional patents once they are filed and how they will be used to help with future development.

Contact:

CTT Pharma - 813-606-0060

SOURCE: CTT Pharmaceutical Holdings, Inc.

View the original press release on ACCESS Newswire

FAQ

What patent approval did CTT Pharma (CTTH) recently receive from the European Patent Office?

CTT Pharma received notification of an intention to grant from the European Patent Office for additional claims to their original European Patent, specifically strengthened for diabetes-related drugs.

How does CTT Pharma (CTTH) plan to use their micelle technology with Liraglutide?

Since Liraglutide's patent has expired, CTT Pharma plans to explore opportunities to utilize their micelle technology to enhance the delivery of this diabetes medication.

What are CTT Pharma's (CTTH) patent expansion plans for 2025?

CTT Pharma plans to file provisional patents in 2025 to further protect and strengthen their technology in both the United States and European markets.

What market opportunity is CTT Pharma (CTTH) targeting with their micelle technology?

CTT Pharma is targeting the diabetes drug market, offering enhanced drug delivery systems for pharmaceutical companies with current patented diabetes drugs and those in development.

How will CTT Pharma's (CTTH) patent strategy affect their future development?

CTT Pharma will use their strengthened patents and new provisional patents to support future development, with specific details to be shared with shareholders after the patents are filed.